Actinogen Ltd Stock
€0.017
Your prediction
Pros and Cons of Actinogen Ltd in the next few years
Pros
Cons
Performance of Actinogen Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Actinogen Ltd | - | 0.000% | 3.030% | -29.167% | 36.000% | -43.333% | -57.500% |
| TALI Digital Ltd. | - | 0.000% | 0.000% | -66.667% | 0.000% | -98.113% | -92.857% |
| Immutep Ltd. | -11.110% | 31.068% | 20.536% | 81.208% | 29.808% | 0.372% | 107.692% |
| Alterity Therapeutics Ltd. ADR | - | 1.235% | 26.154% | -28.070% | -20.388% | -85.614% | -88.506% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Actinogen, a biotechnology & medical research company, appears to be in a growth phase, as evidenced by its increasing total assets, cash, and receivables. However, the financials also show negative working capital and significant net losses, indicating that there are areas of concern. In this analysis, a closer look at the pros and cons of the company's financials will provide a comprehensive assessment of its current position and future prospects.
Increasing Total Assets: Over the period between 2020 and 2022, Actinogen's total assets have grown from AUD 11,936,173.00 to AUD 23,306,351.00, indicating that the company is experiencing growth and expanding its operations.
Rising Cash and Cash Equivalents: The firm's cash position has also increased, with cash and cash equivalents rising from AUD 3,565,000.00 in 2020 to AUD 12100,270.00 in 2022. This increase offers liquidity and flexibility to fund future projects and expansions.